Oncocyte (IMDX) Financials

Oncocyte logo
$1.77 -0.09 (-4.84%)
As of 03:22 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Annual Income Statements for Oncocyte

Annual Income Statements for Oncocyte

This table shows Oncocyte's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders
-8.74 -11 -19 -16 -22 -30 -64 -73 -29 -61 -50
Consolidated Net Income / (Loss)
-8.74 -11 -19 -16 -22 -30 -64 -73 -28 -61 -50
Net Income / (Loss) Continuing Operations
-8.74 -11 -19 -16 -22 -30 -44 -19 -25 -61 -50
Total Pre-Tax Income
-8.74 -11 -19 -16 -22 -31 -53 -19 -25 -61 -50
Total Operating Income
-8.72 -11 -19 -15 -22 -30 -54 -18 -25 -61 -51
Total Gross Profit
0.00 0.00 0.00 0.00 0.00 -0.64 1.42 -0.02 0.41 0.74 2.30
Total Revenue
0.00 0.00 0.00 0.00 0.00 1.22 2.20 0.96 1.50 1.88 4.06
Operating Revenue
- - - - 0.00 1.22 2.20 0.96 1.50 1.88 4.06
Total Cost of Revenue
0.00 0.00 0.00 0.00 0.00 1.86 0.70 0.98 1.09 1.14 1.76
Operating Cost of Revenue
- - - - 0.00 1.86 0.70 0.98 1.09 1.14 1.76
Total Operating Expenses
8.72 11 19 15 22 29 55 18 26 62 53
Selling, General & Admin Expense
3.87 4.27 9.23 7.01 13 17 22 22 11 10 11
Marketing Expense
0.32 1.20 2.44 1.68 2.16 6.49 0.55 1.13 2.80 3.94 6.34
Research & Development Expense
4.53 5.68 7.17 6.51 6.79 9.80 5.04 7.30 9.29 9.84 16
Impairment Charge
- - - - - - 0.00 19 6.76 42 15
Other Special Charges / (Income)
- - - - 0.00 -4.01 27 -31 -4.48 -4.11 5.95
Total Other Income / (Expense), net
-0.02 -0.03 -0.53 -0.55 -0.19 -1.48 0.66 -0.62 0.28 0.38 0.90
Interest Expense
- - 0.22 0.22 -0.15 0.25 -0.93 0.08 0.05 0.08 0.11
Other Income / (Expense), net
0.00 0.00 -0.31 -0.34 -0.05 0.32 - -0.53 0.33 0.46 1.01
Income Tax Expense
- - - - 0.00 -1.25 -9.26 - - 0.00 0.00
Basic Earnings per Share
($0.42) ($0.42) ($0.64) ($0.42) ($0.44) ($0.46) ($0.72) ($13.25) ($3.75) ($4.66) ($1.65)
Weighted Average Basic Shares Outstanding
21.01M 26.53M 30.20M 37.85M 51.30M 65.48M 88.92M 5.54M 7.65M 13.07M 30.48M
Diluted Earnings per Share
($0.42) ($0.42) ($0.64) ($0.42) ($0.44) ($0.46) - ($13.25) ($3.75) ($4.66) ($1.65)
Weighted Average Diluted Shares Outstanding
21.01M 26.53M 30.20M 37.85M 51.30M 65.48M 88.92M 5.54M 7.65M 13.07M 30.48M
Weighted Average Basic & Diluted Shares Outstanding
21.01M 26.53M 30.20M 37.85M 51.30M 65.48M 88.92M - - 28.60M 32.17M

Quarterly Income Statements for Oncocyte

This table shows Oncocyte's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Total Costs & Expenses
- - - - - - 11 - - - 4.10
Net Income / (Loss) Attributable to Common Shareholders
-9.34 -4.59 -13 -34 -6.67 -9.74 -11 -23 -4.29 -11 -3.58
Consolidated Net Income / (Loss)
-9.13 -4.53 -13 -34 -6.67 -9.74 -11 -23 -4.29 -11 -3.58
Net Income / (Loss) Continuing Operations
-9.13 -4.53 -13 -34 -6.67 -9.74 -11 -23 -4.29 -11 -3.58
Total Pre-Tax Income
-9.13 -4.53 -13 -34 -6.67 -9.74 -11 -23 -4.29 -11 -3.58
Total Operating Income
-9.27 -4.63 -14 -34 -6.80 -9.84 -11 -23 -4.41 -11 -3.68
Total Gross Profit
0.05 0.05 0.05 0.60 1.33 0.34 0.14 0.48 0.02 0.16 0.42
Total Revenue
0.18 0.10 0.12 1.49 2.14 0.52 0.26 1.14 0.03 0.24 0.56
Operating Revenue
0.18 0.10 0.12 1.49 2.14 0.52 0.26 1.14 0.03 0.24 0.56
Total Cost of Revenue
0.13 0.05 0.07 0.89 0.81 0.18 0.12 0.66 0.02 0.08 0.14
Operating Cost of Revenue
0.13 0.05 0.07 0.89 0.81 0.18 0.12 0.66 0.02 0.08 0.14
Total Operating Expenses
9.31 4.68 14 34 8.12 10 11 24 4.43 12 4.10
Selling, General & Admin Expense
2.67 2.41 2.57 2.56 3.12 2.65 2.55 2.33 2.99 2.87 2.79
Marketing Expense
0.85 0.85 1.04 1.20 1.21 1.46 1.39 2.29 2.40 1.92 1.61
Research & Development Expense
2.31 2.45 2.82 2.26 2.92 3.27 3.88 5.82 4.95 4.49 3.79
Other Special Charges / (Income)
3.48 -1.03 7.14 -14 0.88 2.80 3.38 -1.12 -5.92 2.28 -4.09
Total Other Income / (Expense), net
0.14 0.10 0.02 0.12 0.13 0.10 0.19 0.48 0.12 0.14 0.10
Interest Expense
0.02 0.01 0.03 0.03 0.03 0.03 0.03 0.03 0.02 0.02 0.02
Other Income / (Expense), net
0.15 0.11 0.05 0.15 0.16 0.13 0.22 0.51 0.15 0.16 0.11
Income Tax Expense
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Basic Earnings per Share
($1.13) ($0.36) ($0.98) ($2.56) ($0.26) ($0.30) ($0.34) ($0.75) ($0.12) ($0.31) ($0.10)
Weighted Average Basic Shares Outstanding
8.26M 12.87M 13.71M 13.07M 25.69M 32.02M 32.03M 30.48M 34.52M 36.75M 36.86M
Diluted Earnings per Share
($1.13) ($0.36) ($0.98) ($2.56) ($0.26) ($0.30) ($0.34) ($0.75) ($0.12) ($0.31) ($0.10)
Weighted Average Diluted Shares Outstanding
8.26M 12.87M 13.71M 13.07M 25.69M 32.02M 32.03M 30.48M 34.52M 36.75M 36.86M
Weighted Average Basic & Diluted Shares Outstanding
13.36M 13.37M 16.84M 28.60M 28.60M 28.62M 28.66M 32.17M 32.29M 32.72M 32.76M

Annual Cash Flow Statements for Oncocyte

This table details how cash moves in and out of Oncocyte's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents
7.74 2.18 -2.57 0.43 16 -15 28 -14 -12 -0.80 2.58
Net Cash From Operating Activities
-4.23 -7.52 -13 -12 -20 -26 -36 -46 -23 -21 -22
Net Cash From Continuing Operating Activities
-4.23 -7.52 -13 -12 -20 -26 -36 -46 -23 -21 -22
Net Income / (Loss) Continuing Operations
-8.74 -11 -19 -16 -22 -30 -64 -73 -28 -61 -50
Consolidated Net Income / (Loss)
-8.74 -11 -19 -16 -22 -30 -64 -73 -28 -61 -50
Depreciation Expense
0.04 0.15 0.34 0.44 0.34 0.31 0.84 1.53 1.59 1.48 2.19
Amortization Expense
0.26 0.24 0.33 0.22 0.10 0.18 3.42 3.70 0.09 0.09 0.01
Non-Cash Adjustments To Reconcile Net Income
3.44 2.93 5.26 2.44 1.62 6.74 5.74 55 13 44 17
Changes in Operating Assets and Liabilities, net
0.77 0.33 0.07 1.01 0.65 -3.28 18 -33 -9.73 -5.57 8.67
Net Cash From Investing Activities
0.32 -0.18 0.84 -0.03 -12 -12 -14 -4.34 -0.93 -0.51 -3.19
Net Cash From Continuing Investing Activities
0.32 -0.18 0.84 -0.03 -12 -12 -14 -4.34 -0.93 -0.51 -3.19
Purchase of Property, Plant & Equipment
-0.50 -0.11 -0.09 -0.03 -0.92 -1.23 -2.25 -4.34 -0.28 -0.52 -3.19
Sale of Property, Plant & Equipment
- - - - - - - 0.00 0.35 0.00 0.00
Net Cash From Financing Activities
12 9.88 9.97 12 48 23 78 36 12 20 28
Net Cash From Continuing Financing Activities
12 9.88 9.97 12 48 23 78 36 12 20 28
Repayment of Debt
0.00 -0.11 -0.40 -1.18 -0.67 -0.45 -1.53 -1.43 -0.12 -0.20 -0.51
Repurchase of Preferred Equity
- - - - - - 0.00 -0.09 -1.12 -5.39 0.00
Repurchase of Common Equity
0.00 -0.77 0.00 -0.07 -3.29 -0.06 -2.68 -0.39 -0.43 -1.37 -0.49
Issuance of Common Equity
12 11 0.00 10 49 21 65 33 14 26 29
Other Financing Activities, net
0.00 0.22 8.38 3.36 -0.03 1.36 17 0.03 0.00 1.38 -0.07
Effect of Exchange Rate Changes
- - - - - - - - - -0.02 -0.12
Cash Interest Paid
0.00 0.03 0.13 0.14 0.17 0.21 0.11 0.02 0.01 0.04 0.09
Cash Income Taxes Paid
- - - - - - - 0.00 0.00 0.00 0.00

Quarterly Cash Flow Statements for Oncocyte

This table details how cash moves in and out of Oncocyte's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Change in Cash & Equivalents
-3.85 3.68 -5.89 5.27 22 -6.74 -5.78 -7.29 16 -11 -6.91
Net Cash From Operating Activities
-3.83 -5.98 -5.53 -5.35 -5.84 -6.28 -4.50 -5.55 -7.64 -9.27 -6.43
Net Cash From Continuing Operating Activities
-3.83 -5.98 -5.53 -5.35 -5.84 -6.28 -4.50 -5.55 -7.64 -9.27 -6.43
Net Income / (Loss) Continuing Operations
-9.13 -4.53 -13 -34 -6.67 -9.74 -11 -23 -4.29 -11 -3.58
Consolidated Net Income / (Loss)
-9.13 -4.53 -13 -34 -6.67 -9.74 -11 -23 -4.29 -11 -3.58
Depreciation Expense
0.31 0.30 0.32 0.54 0.48 0.56 0.58 0.56 0.63 0.67 0.64
Non-Cash Adjustments To Reconcile Net Income
0.63 0.44 0.49 42 0.53 0.58 0.73 15 0.64 0.68 0.83
Changes in Operating Assets and Liabilities, net
4.33 -2.21 7.13 -15 -0.19 2.33 5.04 1.47 -4.62 0.65 -4.32
Net Cash From Investing Activities
-0.02 -0.19 -0.09 -0.21 -0.31 -0.35 -1.05 -1.48 -0.61 -0.78 -0.84
Net Cash From Continuing Investing Activities
-0.02 -0.19 -0.09 -0.21 -0.31 -0.35 -1.05 -1.48 -0.61 -0.78 -0.84
Purchase of Property, Plant & Equipment
-0.02 -0.19 -0.09 -0.21 -0.31 -0.35 -1.05 -1.48 -0.61 -0.78 -0.84
Net Cash From Financing Activities
0.00 9.85 -0.26 11 29 -0.11 -0.12 -0.25 25 -0.56 0.37
Net Cash From Continuing Financing Activities
0.00 9.85 -0.26 11 29 -0.11 -0.12 -0.25 25 -0.56 0.37
Repayment of Debt
0.00 -0.03 -0.09 -0.08 -0.10 -0.11 -0.12 -0.18 -0.14 -0.15 -0.13
Repurchase of Common Equity
0.00 -0.54 - -0.84 -0.49 - - - -1.18 -0.19 -0.01
Other Financing Activities, net
0.00 - - 1.55 - - - -0.07 - - 0.51
Effect of Exchange Rate Changes
- - - -0.00 -0.02 - - -0.02 -0.01 -0.02 -0.01
Cash Interest Paid
0.00 - 0.02 0.03 0.02 0.02 0.02 0.02 0.02 0.02 0.01

Annual Balance Sheets for Oncocyte

This table presents Oncocyte's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets
13 14 10 9.52 40 55 160 100 75 35 26
Total Current Assets
11 13 8.53 8.64 23 9.23 39 26 11 12 15
Cash & Equivalents
8.00 10 7.60 8.03 22 7.14 33 20 9.43 8.64 12
Restricted Cash
- - - - - - - - - 0.00 0.73
Accounts Receivable
- - - - 0.00 0.20 1.44 2.01 0.48 1.61 1.13
Inventories, net
- - - - - - - - 0.00 0.41 0.45
Prepaid Expenses
0.39 0.29 0.17 0.18 0.51 1.21 0.90 0.98 0.64 0.82 1.42
Plant, Property, & Equipment, net
0.58 0.69 0.82 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets
1.23 1.06 0.87 0.88 17 46 120 75 64 23 10
Noncurrent Note & Lease Receivables
- - - - - 3.26 2.78 2.18 1.64 2.76 2.82
Other Noncurrent Operating Assets
0.00 0.08 0.12 0.88 5.94 5.32 7.55 11 5.96 5.96 7.64
Total Liabilities & Shareholders' Equity
13 14 10 9.52 40 55 160 100 75 35 26
Total Liabilities
2.31 4.59 5.81 6.10 9.02 22 94 60 49 47 57
Total Current Liabilities
2.31 4.28 4.45 5.56 4.44 9.00 14 12 7.19 7.28 12
Short-Term Debt
0.00 0.20 1.14 0.80 1.13 2.39 1.31 0.11 2.31 0.23 0.43
Accounts Payable
2.27 4.07 3.32 4.38 3.09 2.72 3.90 3.07 1.41 2.06 3.48
Accrued Expenses
- - - - - 3.47 4.22 3.79 2.77 3.06 3.58
Other Current Liabilities
0.04 - - 0.39 0.23 0.42 3.17 3.13 0.67 1.93 4.59
Total Noncurrent Liabilities
0.00 0.31 1.36 0.53 4.58 13 80 48 42 40 45
Capital Lease Obligations
0.00 0.31 0.29 - 2.68 4.31 3.55 2.73 2.20 2.37 1.69
Other Noncurrent Operating Liabilities
- - - 0.19 0.00 7.12 77 46 40 38 43
Commitments & Contingencies
0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
10 9.86 4.40 3.42 31 33 65 34 20 -12 -31
Total Preferred & Common Equity
10 9.86 4.40 3.42 31 33 65 34 20 -12 -31
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
10 9.86 4.40 3.42 31 33 65 34 20 -12 -31
Common Stock
35 46 60 75 125 157 253 295 310 338 369
Retained Earnings
-24 -35 -55 -71 -94 -124 -188 -261 -290 -351 -401
Accumulated Other Comprehensive Income / (Loss)
-0.35 -0.65 -0.89 0.00 - 0.00 0.04 0.04 0.05 0.02 0.09

Quarterly Balance Sheets for Oncocyte

This table presents Oncocyte's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026 9/30/2026
Total Assets
82 71 75 70 60 51 44 40 29 22
Total Current Assets
17 6.54 9.97 4.79 36 27 21 31 21 14
Cash & Equivalents
14 5.58 9.26 3.36 31 24 19 28 18 11
Restricted Cash
- - - - - - 0.73 0.73 0.73 0.73
Accounts Receivable
1.88 0.16 0.09 0.21 3.54 0.51 0.26 0.16 0.19 0.52
Inventories, net
- - - 0.23 0.46 0.69 0.47 0.38 0.21 0.37
Prepaid Expenses
0.67 0.74 0.60 0.63 1.24 1.35 1.24 1.05 1.66 1.24
Plant, Property, & Equipment, net
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets
65 64 65 65 24 24 23 9.91 8.90 7.86
Noncurrent Note & Lease Receivables
1.76 2.20 2.59 3.00 2.59 2.52 2.34 2.46 2.10 1.75
Other Noncurrent Operating Assets
6.30 5.67 5.61 5.89 6.91 6.55 5.61 7.45 6.80 6.12
Total Liabilities & Shareholders' Equity
82 71 75 70 60 51 44 40 29 22
Total Liabilities
39 54 52 61 50 49 53 51 51 46
Total Current Liabilities
8.03 8.33 7.20 9.09 9.68 6.65 7.66 12 10 9.51
Short-Term Debt
- - - 0.61 0.43 0.69 1.06 0.16 0.71 0.83
Accounts Payable
1.96 1.65 1.43 1.86 4.21 1.85 1.66 2.90 2.87 2.01
Accrued Expenses
2.95 3.54 2.43 3.02 3.64 2.58 3.35 4.45 3.02 3.79
Other Current Liabilities
3.03 3.14 3.34 3.60 1.40 1.54 1.60 4.50 3.69 2.88
Total Noncurrent Liabilities
31 46 45 51 40 43 45 39 40 36
Capital Lease Obligations
2.35 - 2.64 2.71 2.07 1.83 1.53 1.31 0.92 0.58
Other Noncurrent Operating Liabilities
29 46 42 49 38 41 44 38 40 36
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
38 12 23 9.71 10 1.10 -9.20 -11 -21 -24
Total Preferred & Common Equity
38 12 23 9.71 10 1.10 -9.20 -11 -21 -24
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
38 12 23 9.71 10 1.10 -9.20 -11 -21 -24
Common Stock
310 311 326 327 367 368 369 394 395 396
Retained Earnings
-272 -299 -304 -317 -357 -367 -378 -405 -416 -420
Accumulated Other Comprehensive Income / (Loss)
0.03 0.04 0.04 0.06 0.04 0.09 0.09 0.07 0.07 0.06

Annual Metrics And Ratios for Oncocyte

This table displays calculated financial ratios and metrics derived from Oncocyte's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding
0.00 28,709,348.00 31,427,067.00 40,664,496.00 51,972,830.00 67,250,639.00 92,231,437.00 118,643,821.00 8,260,762.00 16,835,247.00 28,664,437.00
DEI Adjusted Shares Outstanding
0.00 1,435,467.00 1,571,353.00 2,033,225.00 2,598,642.00 3,362,532.00 4,611,572.00 5,932,191.00 8,260,762.00 16,835,247.00 28,664,437.00
DEI Earnings Per Adjusted Shares Outstanding
0.00 -7.78 -12.33 -7.75 -8.63 -8.90 -13.90 -12.38 -3.48 -3.62 -1.75
Growth Metrics
- - - - - - - - - - -
Revenue Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 80.76% -56.41% 56.89% 25.15% 115.58%
EBITDA Growth
-78.93% -27.78% -72.00% 19.52% -46.76% -32.26% -71.21% 73.12% -73.90% -155.22% 18.81%
EBIT Growth
-74.88% -27.81% -71.97% 18.90% -43.46% -31.83% -82.82% 65.51% -33.86% -144.24% 17.28%
NOPAT Growth
-75.31% -27.78% -69.20% 19.35% -46.29% -33.60% -80.83% 66.50% -39.67% -142.84% 16.25%
Net Income Growth
-75.19% -27.85% -73.49% 18.69% -42.35% -33.47% -114.14% -13.74% 61.89% -118.36% 17.21%
EPS Growth
-55.56% 0.00% -52.38% 34.38% -4.76% -4.55% 0.00% 0.00% 71.70% -24.27% 64.59%
Operating Cash Flow Growth
-263.32% -77.87% -77.94% 12.97% -69.24% -31.78% -38.34% -26.79% 48.81% 11.30% -7.23%
Free Cash Flow Firm Growth
0.00% 1.70% -134.17% 40.39% -175.15% -68.79% 41.61% -31.94% 44.07% 77.54% -237.11%
Invested Capital Growth
0.00% -1,597.50% 28.33% -166.58% 180.40% 553.82% -75.00% 328.04% -5.32% -188.36% -127.48%
Revenue Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% 70.31% -52.63% 176.27% 2.73% 165.30% -7.88%
EBITDA Q/Q Growth
0.00% 4.12% -4.16% -4.20% -16.66% 1.16% -16.77% 18.55% -27.12% -41.35% 18.05%
EBIT Q/Q Growth
0.00% 3.85% -4.49% -3.72% -16.07% 5.10% -21.47% 13.99% -19.11% -40.63% 17.39%
NOPAT Q/Q Growth
0.00% 3.85% -4.43% -1.02% -18.53% 4.05% -19.92% 16.46% -21.99% -40.02% 16.62%
Net Income Q/Q Growth
0.00% 3.77% -4.64% -3.54% -18.21% 5.21% -85.68% -14.25% 51.06% -40.61% 17.37%
EPS Q/Q Growth
0.00% 10.64% -4.92% 4.55% -12.82% 2.13% 0.00% -14.25% 48.77% -56.38% 13.16%
Operating Cash Flow Q/Q Growth
0.00% -12.22% -6.61% 7.08% -16.90% -3.33% -2.63% -6.01% 18.30% -4.69% -0.77%
Free Cash Flow Firm Q/Q Growth
0.00% 0.00% -3.68% 16.38% -60.93% 7.00% 69.18% -246.58% -326.08% 61.07% -72.34%
Invested Capital Q/Q Growth
0.00% -0.54% -5.95% -85.86% 362.50% 12.85% -91.33% -58.22% -32.50% -289.38% -60.03%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
0.00% 0.00% 0.00% 0.00% 0.00% -52.55% 64.60% -1.88% 27.48% 39.34% 56.67%
EBITDA Margin
0.00% 0.00% 0.00% 0.00% 0.00% -2,375.90% -2,250.41% -1,388.00% -1,538.46% -3,137.43% -1,181.65%
Operating Margin
0.00% 0.00% 0.00% 0.00% 0.00% -2,443.34% -2,444.27% -1,878.60% -1,672.39% -3,245.14% -1,260.76%
EBIT Margin
0.00% 0.00% 0.00% 0.00% 0.00% -2,416.69% -2,444.27% -1,934.13% -1,650.23% -3,220.57% -1,235.83%
Profit (Net Income) Margin
0.00% 0.00% 0.00% 0.00% 0.00% -2,461.51% -2,916.15% -7,609.81% -1,848.37% -3,225.04% -1,238.52%
Tax Burden Percent
100.00% 100.00% 100.00% 100.00% 100.00% 95.98% 121.23% 391.69% 111.77% 100.00% 100.00%
Interest Burden Percent
100.22% 100.25% 101.13% 101.39% 100.61% 106.12% 98.41% 100.45% 100.21% 100.14% 100.22%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% -176.35% -294.13% -93.30% -82.58% -3,543.01% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% -131.50% -221.68% 61.71% 7.67% -3,214.18% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 83.28% 164.25% -45.81% -2.66% 2,632.15% 0.00%
Return on Equity (ROE)
-83.85% -110.14% -271.64% -402.61% -130.91% -93.07% -129.88% -139.11% -85.23% -910.86% 229.65%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% 0.00% -721.90% -323.29% -174.12% -217.55% -77.11% 0.00% 0.00%
Operating Return on Assets (OROA)
0.00% 0.00% 0.00% 0.00% 0.00% -61.69% -49.98% -14.27% -28.35% -110.17% -164.75%
Return on Assets (ROA)
0.00% 0.00% 0.00% 0.00% 0.00% -62.83% -59.63% -56.15% -31.75% -110.32% -165.10%
Return on Common Equity (ROCE)
-83.85% -110.14% -271.64% -402.61% -130.91% -93.07% -129.88% -132.07% -71.60% -560.33% 229.65%
Return on Equity Simple (ROE_SIMPLE)
-83.85% -113.24% -440.04% -460.24% -72.72% -89.39% -98.28% -212.59% -135.73% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-6.10 -7.80 -13 -11 -16 -21 -38 -13 -18 -43 -36
NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% -1,710.34% -1,710.99% -1,315.02% -1,170.67% -2,271.59% -882.54%
Net Nonoperating Expense Percent (NNEP)
-49.96% -30.04% -69.59% -77.59% -39.17% -44.85% -72.45% -155.01% -90.25% -328.83% -177.85%
Return On Investment Capital (ROIC_SIMPLE)
- - - - - - - - -70.42% 441.55% 121.95%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 152.55% 31.71% 101.88% 72.52% 60.66% 43.33%
SG&A Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 1,380.59% 1,014.19% 2,284.03% 743.98% 542.48% 262.22%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 805.92% 229.07% 762.11% 618.36% 523.07% 392.11%
Operating Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 2,390.79% 2,508.87% 1,876.72% 1,699.87% 3,284.48% 1,317.44%
Earnings before Interest and Taxes (EBIT)
-8.72 -11 -19 -16 -22 -29 -54 -19 -25 -61 -50
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-8.42 -11 -18 -15 -22 -29 -49 -13 -23 -59 -48
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
0.00 20.52 33.19 16.39 3.79 4.80 3.07 1.11 1.01 0.00 0.00
Price to Tangible Book Value (P/TBV)
0.00 22.81 39.96 16.39 3.79 17.31 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)
0.00 0.00 0.00 0.00 0.00 132.18 91.06 39.74 13.74 21.30 53.02
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 28.52 7.22 33.47 1.18 1.01 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
0.00 0.00 0.00 0.00 0.00 121.47 77.87 26.92 13.88 18.09 50.50
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.00 0.05 0.57 0.34 0.19 0.25 0.07 0.07 0.18 -0.21 -0.07
Long-Term Debt to Equity
0.00 0.03 0.31 0.10 0.15 0.17 0.05 0.07 0.09 -0.19 -0.05
Financial Leverage
-1.01 -1.11 -1.25 -1.68 -1.02 -0.63 -0.74 -0.74 -0.35 -0.82 0.37
Leverage Ratio
1.22 1.34 1.73 2.52 1.44 1.48 2.18 2.48 2.68 8.26 -1.39
Compound Leverage Factor
1.22 1.34 1.75 2.56 1.45 1.57 2.14 2.49 2.69 8.27 -1.39
Debt to Total Capital
0.00% 4.94% 36.19% 25.10% 15.61% 19.69% 6.93% 6.69% 15.00% -26.84% -7.22%
Short-Term Debt to Total Capital
0.00% 1.95% 16.49% 17.51% 3.08% 5.73% 1.87% 0.26% 7.68% -2.36% -1.46%
Long-Term Debt to Total Capital
0.00% 2.99% 19.70% 7.59% 12.54% 13.96% 5.06% 6.43% 7.32% -24.48% -5.76%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 12.50% 17.02% 0.00% 0.00%
Common Equity to Total Capital
100.00% 95.06% 63.81% 74.90% 84.39% 80.31% 93.07% 80.82% 67.97% 126.84% 107.22%
Debt to EBITDA
0.00 -0.05 -0.14 -0.08 -0.26 -0.28 -0.10 -0.21 -0.20 -0.04 -0.04
Net Debt to EBITDA
0.00 1.11 0.32 0.49 1.27 0.45 0.59 1.32 0.21 0.10 0.21
Long-Term Debt to EBITDA
0.00 -0.03 -0.07 -0.02 -0.21 -0.20 -0.07 -0.21 -0.10 -0.04 -0.04
Debt to NOPAT
0.00 -0.07 -0.19 -0.11 -0.37 -0.39 -0.13 -0.23 -0.26 -0.06 -0.06
Net Debt to NOPAT
0.00 1.53 0.44 0.69 1.78 0.63 0.77 1.40 0.28 0.14 0.28
Long-Term Debt to NOPAT
0.00 -0.04 -0.10 -0.03 -0.29 -0.28 -0.09 -0.22 -0.13 -0.06 -0.05
Altman Z-Score
0.00 21.22 1.88 -9.96 3.20 -0.45 -1.28 -3.71 -6.18 -18.97 -25.64
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 5.06% 16.00% 38.48% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
4.72 2.97 1.91 1.55 5.17 1.03 2.77 2.11 1.49 1.62 1.27
Quick Ratio
4.55 2.90 1.88 1.52 5.06 0.89 2.50 1.85 1.38 1.41 1.05
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-5.98 -5.88 -14 -8.21 -23 -38 -22 -29 -16 -3.69 -12
Operating Cash Flow to CapEx
-845.80% -7,096.23% -14,708.79% -37,577.42% -2,147.60% -2,117.36% -1,599.51% -1,049.95% 0.00% -4,040.82% -696.51%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 -63.46 -38.01 0.00 -151.30 0.00 -353.90 -315.97 -43.94 -114.15
Operating Cash Flow to Interest Expense
0.00 0.00 -61.68 -53.93 0.00 -103.10 0.00 -549.01 -448.56 -246.30 -203.52
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 -62.10 -54.07 0.00 -107.96 0.00 -601.30 -447.15 -252.39 -232.74
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.03 0.02 0.01 0.02 0.03 0.13
Accounts Receivable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 2.68 0.56 1.20 1.79 2.96
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 4.11
Fixed Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.64 0.21 0.28 0.49 0.66 0.63
Days Sales Outstanding (DSO)
0.00 0.00 0.00 0.00 0.00 0.00 136.17 657.04 303.07 203.46 123.36
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 88.91
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 570.72 1,731.00 1,302.37 749.25 554.06 575.65
Cash Conversion Cycle (CCC)
0.00 0.00 0.00 0.00 0.00 -570.72 -1,594.83 -645.33 -446.18 -350.60 -363.37
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
-0.12 -2.04 -1.46 -3.89 3.13 20 5.11 22 21 -18 -42
Invested Capital Turnover
0.00 0.00 0.00 0.00 0.00 0.10 0.17 0.07 0.07 1.56 -0.14
Increase / (Decrease) in Invested Capital
-0.12 -1.92 0.58 -2.43 7.02 17 -15 17 -1.17 -39 -23
Enterprise Value (EV)
0.00 191 140 49 89 148 171 26 21 34 205
Market Capitalization
0.00 202 146 56 117 161 200 38 21 40 215
Book Value per Share
$0.50 $0.34 $0.14 $0.08 $0.59 $0.50 $0.71 $0.29 $2.48 ($0.73) ($1.10)
Tangible Book Value per Share
$0.44 $0.31 $0.12 $0.08 $0.59 $0.14 ($0.16) ($0.23) ($4.37) ($1.60) ($1.10)
Total Capital
10 10 6.90 4.57 37 42 70 42 30 -9.68 -29
Total Debt
0.00 0.51 2.50 1.15 5.71 8.21 4.86 2.84 4.52 2.60 2.12
Total Long-Term Debt
0.00 0.31 1.36 0.35 4.58 5.82 3.55 2.73 2.20 2.37 1.69
Net Debt
-11 -12 -5.86 -7.32 -28 -13 -29 -18 -4.91 -6.04 -10
Capital Expenditures (CapEx)
0.50 0.11 0.09 0.03 0.92 1.23 2.25 4.34 -0.07 0.51 3.19
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-1.93 -3.79 -3.15 -4.58 -2.81 -5.20 -7.52 -6.89 -3.61 -3.92 -8.65
Debt-free Net Working Capital (DFNWC)
8.61 8.62 5.21 3.88 20 2.62 26 14 5.82 4.71 3.66
Net Working Capital (NWC)
8.61 8.42 4.07 3.08 19 0.23 25 13 3.50 4.48 3.23
Net Nonoperating Expense (NNE)
2.63 3.37 6.18 5.11 6.86 9.13 26 60 10 18 14
Net Nonoperating Obligations (NNO)
-11 -12 -5.86 -7.32 -28 -13 -60 -18 -4.87 -6.04 -10
Total Depreciation and Amortization (D&A)
0.30 0.39 0.66 0.65 0.45 0.50 4.26 5.23 1.68 1.56 2.20
Debt-free, Cash-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% -427.47% -341.95% -718.89% -240.45% -208.61% -213.39%
Debt-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 215.46% 1,198.18% 1,413.26% 387.09% 250.51% 90.23%
Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 18.91% 1,138.44% 1,401.88% 233.13% 238.38% 79.68%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($8.40) ($8.40) ($12.80) ($8.40) ($8.80) ($9.20) ($14.40) ($13.20) ($3.75) ($4.66) ($1.65)
Adjusted Weighted Average Basic Shares Outstanding
1.05M 1.47M 1.57M 2.60M 3.12M 4.45M 4.61M 5.54M 7.65M 13.07M 30.48M
Adjusted Diluted Earnings per Share
($8.40) ($8.40) ($12.80) ($8.40) ($8.80) ($9.20) ($14.40) $0.00 ($3.75) ($4.66) ($1.65)
Adjusted Weighted Average Diluted Shares Outstanding
1.05M 1.47M 1.57M 2.60M 3.12M 4.45M 4.61M 0.00 7.65M 13.07M 30.48M
Adjusted Basic & Diluted Earnings per Share
($8.40) ($8.40) ($12.80) ($8.40) ($8.80) ($9.20) ($14.40) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
1.05M 1.33M 1.51M 1.89M 2.56M 3.27M 4.45M 0.00 0.00 28.60M 32.17M
Normalized Net Operating Profit after Tax (NOPAT)
-6.10 -7.80 -13 -11 -16 -24 -19 -21 -16 -16 -21
Normalized NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% -1,941.18% -842.64% -2,216.33% -1,064.58% -865.12% -527.86%
Pre Tax Income Margin
0.00% 0.00% 0.00% 0.00% 0.00% -2,564.64% -2,405.41% -1,942.80% -1,653.69% -3,225.04% -1,238.52%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 -88.29 -71.94 0.00 -116.62 0.00 -223.24 -476.98 -721.18 -459.75
NOPAT to Interest Expense
0.00 0.00 -60.80 -49.27 0.00 -82.53 0.00 -151.78 -338.37 -508.68 -328.32
EBIT Less CapEx to Interest Expense
0.00 0.00 -88.71 -72.08 0.00 -121.48 0.00 -275.53 -475.58 -727.27 -488.97
NOPAT Less CapEx to Interest Expense
0.00 0.00 -61.22 -49.41 0.00 -87.40 0.00 -204.07 -336.97 -514.77 -357.54
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% -6.92% 0.00% -0.41% -14.66% -0.19% -4.17% -0.53% -1.54% -2.27% -0.97%

Quarterly Metrics And Ratios for Oncocyte

This table displays calculated financial ratios and metrics derived from Oncocyte's official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
DEI Shares Outstanding
8,260,762.00 13,364,637.00 13,368,387.00 16,835,247.00 28,599,285.00 28,599,285.00 28,619,749.00 28,664,437.00 32,167,978.00 32,290,167.00 32,724,284.00
DEI Adjusted Shares Outstanding
8,260,762.00 13,364,637.00 13,368,387.00 16,835,247.00 28,599,285.00 28,599,285.00 28,619,749.00 28,664,437.00 32,167,978.00 32,290,167.00 32,724,284.00
DEI Earnings Per Adjusted Shares Outstanding
-1.13 -0.34 -1.01 -1.99 -0.23 -0.34 -0.38 -0.80 -0.13 -0.35 -0.11
Growth Metrics
- - - - - - - - - - -
Revenue Growth
-40.74% -77.54% -73.19% 373.25% 1,114.77% 398.08% 126.09% -23.35% -98.50% -53.86% 115.00%
EBITDA Growth
-236.28% 46.63% -116.93% -110.28% 29.94% -118.26% 21.96% 32.06% 40.89% -15.47% 71.49%
EBIT Growth
-252.66% 45.64% -107.91% -109.53% 27.12% -114.88% 19.59% 31.52% 35.76% -15.67% 67.09%
NOPAT Growth
-210.89% 44.15% -107.51% -107.84% 26.63% -112.48% 18.25% 30.31% 35.09% -15.85% 66.73%
Net Income Growth
-400.99% 45.64% -107.94% -109.55% 26.93% -115.06% 19.56% 31.50% 35.69% -15.58% 67.03%
EPS Growth
-382.50% 66.36% -20.99% -46.29% 76.99% 16.67% 65.31% 70.70% 53.85% -3.33% 70.59%
Operating Cash Flow Growth
53.86% 12.50% -46.72% -20.95% -52.45% -5.04% 18.59% -3.63% -30.83% -50.11% -39.06%
Free Cash Flow Firm Growth
25.21% 78.81% -32.44% 252.55% 54.90% 119.05% 141.64% -55.22% -32.65% -68.13% -78.84%
Invested Capital Growth
-66.54% -51.20% -68.51% -188.36% -261.38% -228.48% -369.20% -127.48% -108.45% -84.67% -32.62%
Revenue Q/Q Growth
-43.95% -40.91% 10.58% 1,192.17% 43.88% -75.77% -49.81% 338.08% -97.19% 646.88% 133.89%
EBITDA Q/Q Growth
43.92% 52.20% -212.73% -150.86% 81.31% -48.89% -11.83% -118.40% 83.74% -190.84% 72.39%
EBIT Q/Q Growth
42.96% 50.38% -197.70% -148.71% 80.16% -46.30% -11.40% -111.82% 81.39% -163.42% 68.31%
NOPAT Q/Q Growth
42.72% 50.02% -191.77% -148.81% 79.78% -44.76% -12.25% -112.12% 81.17% -158.37% 67.76%
Net Income Q/Q Growth
42.92% 50.38% -197.86% -148.36% 80.09% -46.04% -11.41% -111.49% 81.31% -162.47% 68.21%
EPS Q/Q Growth
35.43% 68.14% -172.22% -161.22% 89.84% -15.38% -13.33% -120.59% 84.00% -158.33% 67.74%
Operating Cash Flow Q/Q Growth
13.43% -56.08% 7.49% 3.24% -9.12% -7.19% 28.30% -23.17% -37.76% -21.32% 30.59%
Free Cash Flow Firm Q/Q Growth
258.13% -15.15% -15.10% 33.91% 60.57% 19.99% -6.34% -75.18% 141.51% -43.23% -37.81%
Invested Capital Q/Q Growth
-45.27% 41.82% -39.88% -289.38% 0.05% -12.90% -25.97% -60.03% 8.41% -0.02% 9.54%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
25.57% 48.08% 43.48% 40.04% 61.97% 67.57% 53.46% 42.49% 46.88% 65.69% 75.13%
EBITDA Margin
-4,988.07% -4,034.62% -11,410.43% -2,215.21% -287.70% -1,767.95% -3,938.85% -1,963.65% -11,362.50% -4,424.69% -522.36%
Operating Margin
-5,265.34% -4,453.85% -11,752.17% -2,262.92% -318.01% -1,900.00% -4,249.23% -2,057.51% -13,790.63% -4,770.71% -657.60%
EBIT Margin
-5,178.41% -4,348.08% -11,706.09% -2,253.10% -310.66% -1,875.87% -4,163.46% -2,013.08% -13,334.38% -4,702.93% -637.21%
Profit (Net Income) Margin
-5,186.93% -4,355.77% -11,733.04% -2,255.11% -312.02% -1,880.70% -4,174.62% -2,015.36% -13,406.25% -4,711.30% -640.25%
Tax Burden Percent
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent
100.16% 100.18% 100.23% 100.09% 100.44% 100.26% 100.27% 100.11% 100.54% 100.18% 100.48%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
-225.20% -130.06% -288.92% -2,470.64% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
-190.32% -118.35% -220.70% -2,287.80% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
47.74% 36.63% 49.98% 1,873.52% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)
-177.46% -93.43% -238.94% -597.12% -428.96% -532.89% -23,603.11% 229.65% 20,228.75% 488.68% 252.21%
Cash Return on Invested Capital (CROIC)
-24.87% -35.64% -46.96% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)
-93.08% -54.83% -109.35% -77.07% -18.18% -127.53% -321.11% -268.36% -515.72% -196.45% -38.21%
Return on Assets (ROA)
-93.23% -54.92% -109.60% -77.14% -18.26% -127.86% -321.97% -268.66% -518.50% -196.80% -38.39%
Return on Common Equity (ROCE)
-145.53% -87.22% -216.40% -367.33% -344.68% -532.89% -23,603.11% 229.65% 20,228.75% 488.68% 252.21%
Return on Equity Simple (ROE_SIMPLE)
-344.69% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-6.49 -3.24 -9.46 -24 -4.76 -6.89 -7.73 -16 -3.09 -7.98 -2.57
NOPAT Margin
-3,685.74% -3,117.69% -8,226.52% -1,584.04% -222.61% -1,330.00% -2,974.46% -1,440.25% -9,653.44% -3,339.50% -460.32%
Net Nonoperating Expense Percent (NNEP)
-34.88% -11.71% -68.23% -182.84% -11.21% -20.10% -36.98% -80.71% -4.29% -16.98% -7.40%
Return On Investment Capital (ROIC_SIMPLE)
-55.98% -12.80% -72.59% 243.25% -37.40% -190.26% 116.98% 55.90% 33.49% 40.56% 11.30%
Cost of Revenue to Revenue
74.43% 51.92% 56.52% 59.96% 38.03% 32.43% 46.54% 57.51% 53.13% 34.31% 24.87%
SG&A Expenses to Revenue
1,518.75% 2,314.42% 2,230.43% 172.21% 145.70% 511.00% 978.85% 204.21% 9,346.88% 1,202.09% 498.21%
R&D to Revenue
1,313.64% 2,358.65% 2,449.57% 151.88% 136.76% 633.40% 1,491.54% 510.71% 15,478.13% 1,876.99% 678.53%
Operating Expenses to Revenue
5,290.91% 4,501.92% 11,795.65% 2,302.96% 379.98% 1,967.57% 4,302.69% 2,100.00% 13,837.50% 4,836.40% 732.74%
Earnings before Interest and Taxes (EBIT)
-9.11 -4.52 -13 -33 -6.64 -9.72 -11 -23 -4.27 -11 -3.56
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-8.78 -4.20 -13 -33 -6.15 -9.16 -10 -22 -3.64 -11 -2.92
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
2.09 1.74 3.92 0.00 8.56 78.66 0.00 0.00 0.00 0.00 0.00
Price to Tangible Book Value (P/TBV)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)
17.51 38.54 53.74 21.30 22.77 20.29 21.59 53.02 54.14 114.08 59.66
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
2.11 2.04 3.94 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
17.34 32.07 53.68 18.09 15.35 15.18 17.76 50.50 40.04 103.98 54.41
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.00 0.12 0.34 -0.21 0.25 2.30 -0.28 -0.07 -0.14 -0.08 -0.06
Long-Term Debt to Equity
0.00 0.12 0.28 -0.19 0.20 1.67 -0.17 -0.05 -0.12 -0.04 -0.02
Financial Leverage
-0.25 -0.31 -0.23 -0.82 -1.26 -1.19 -32.77 0.37 118.36 1.91 0.81
Leverage Ratio
2.55 2.28 2.91 8.26 4.84 5.26 221.66 -1.39 -213.08 -3.96 -1.97
Compound Leverage Factor
2.55 2.29 2.92 8.26 4.86 5.28 222.25 -1.39 -214.23 -3.97 -1.98
Debt to Total Capital
0.00% 10.41% 25.49% -26.84% 19.70% 69.68% -39.10% -7.22% -15.89% -8.24% -6.17%
Short-Term Debt to Total Capital
0.00% 0.00% 4.71% -2.36% 3.40% 19.03% -15.97% -1.46% -1.72% -3.59% -3.63%
Long-Term Debt to Total Capital
0.00% 10.41% 20.78% -24.48% 16.30% 50.65% -23.13% -5.76% -14.17% -4.65% -2.54%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
31.51% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
68.49% 89.59% 74.51% 126.84% 80.30% 30.32% 139.10% 107.22% 115.89% 108.24% 106.17%
Debt to EBITDA
0.00 -0.08 -0.08 -0.04 -0.04 -0.04 -0.04 -0.04 -0.03 -0.03 -0.04
Net Debt to EBITDA
0.00 0.19 0.00 0.10 0.51 0.35 0.29 0.21 0.60 0.36 0.26
Long-Term Debt to EBITDA
0.00 -0.08 -0.06 -0.04 -0.04 -0.03 -0.03 -0.04 -0.03 -0.02 -0.01
Debt to NOPAT
0.00 -0.10 -0.11 -0.06 -0.06 -0.06 -0.06 -0.06 -0.04 -0.05 -0.05
Net Debt to NOPAT
0.00 0.26 0.00 0.14 0.70 0.49 0.39 0.28 0.81 0.48 0.34
Long-Term Debt to NOPAT
0.00 -0.10 -0.09 -0.06 -0.05 -0.04 -0.04 -0.05 -0.04 -0.03 -0.02
Altman Z-Score
-6.06 -5.37 -6.64 -16.42 -7.01 -9.19 -11.30 -22.16 -12.54 -18.33 -25.71
Noncontrolling Interest Sharing Ratio
17.99% 6.65% 9.43% 38.48% 19.65% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
0.78 1.38 0.53 1.62 3.75 4.04 2.79 1.27 2.54 2.00 1.46
Quick Ratio
0.69 1.30 0.39 1.41 3.57 3.73 2.47 1.05 2.36 1.74 1.21
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
16 14 12 15 25 30 28 6.94 17 9.52 5.92
Operating Cash Flow to CapEx
-15,958.33% -3,129.84% -6,356.32% -2,500.47% -1,901.95% -1,799.14% -428.76% -374.92% -1,246.17% -1,189.73% -764.92%
Free Cash Flow to Firm to Interest Expense
1,071.07 1,704.08 373.37 516.64 858.16 1,194.46 964.43 266.94 728.78 475.78 348.11
Operating Cash Flow to Interest Expense
-255.33 -747.25 -178.39 -178.37 -201.34 -251.16 -155.24 -213.27 -332.13 -463.40 -378.41
Operating Cash Flow Less CapEx to Interest Expense
-256.93 -771.13 -181.19 -185.50 -211.93 -265.12 -191.45 -270.15 -358.78 -502.35 -427.88
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.02 0.01 0.01 0.03 0.06 0.07 0.08 0.13 0.04 0.04 0.06
Accounts Receivable Turnover
1.34 1.14 0.68 1.79 2.08 14.26 18.85 2.96 1.05 4.74 5.06
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 5.67 4.11 2.29 1.92 2.09
Fixed Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover
0.35 0.36 0.37 0.66 0.62 1.18 1.13 0.63 0.27 0.37 0.48
Days Sales Outstanding (DSO)
272.30 321.29 538.23 203.46 175.76 25.59 19.36 123.36 346.18 76.93 72.11
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 64.37 88.91 159.71 190.32 174.63
Days Payable Outstanding (DPO)
1,034.29 1,002.97 991.42 554.06 586.14 308.85 321.87 575.65 1,349.28 997.93 760.66
Cash Conversion Cycle (CCC)
-762.00 -681.68 -453.19 -350.60 -410.39 -283.25 -238.14 -363.37 -843.39 -730.68 -513.92
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
11 16 9.67 -18 -18 -21 -26 -42 -38 -38 -35
Invested Capital Turnover
0.06 0.04 0.04 1.56 -1.10 -1.86 -0.54 -0.14 -0.07 -0.06 -0.07
Increase / (Decrease) in Invested Capital
-23 -17 -21 -39 -30 -37 -36 -23 -20 -17 -8.49
Enterprise Value (EV)
24 33 38 34 59 65 78 205 78 174 107
Market Capitalization
24 39 38 40 88 86 95 215 106 191 117
Book Value per Share
$1.40 $1.70 $0.73 ($0.73) $0.36 $0.04 ($0.32) ($1.10) ($0.33) ($0.66) ($0.74)
Tangible Book Value per Share
($5.45) ($2.53) ($3.50) ($1.60) ($0.15) ($0.47) ($0.83) ($1.10) ($0.33) ($0.66) ($0.74)
Total Capital
17 25 13 -9.68 13 3.62 -6.61 -29 -9.23 -20 -23
Total Debt
0.00 2.64 3.32 2.60 2.51 2.52 2.59 2.12 1.47 1.62 1.41
Total Long-Term Debt
0.00 2.64 2.71 2.37 2.07 1.83 1.53 1.69 1.31 0.92 0.58
Net Debt
-5.58 -6.62 -0.04 -6.04 -29 -22 -17 -10 -27 -17 -10
Capital Expenditures (CapEx)
0.02 0.19 0.09 0.21 0.31 0.35 1.05 1.48 0.61 0.78 0.84
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-7.37 -6.49 -7.05 -3.92 -4.02 -3.41 -4.64 -8.65 -10 -7.52 -6.56
Debt-free Net Working Capital (DFNWC)
-1.79 2.77 -3.68 4.71 27 21 15 3.66 19 11 5.19
Net Working Capital (NWC)
-1.79 2.77 -4.30 4.48 27 20 14 3.23 19 10 4.37
Net Nonoperating Expense (NNE)
2.64 1.29 4.03 9.97 1.91 2.85 3.12 6.55 1.20 3.28 1.01
Net Nonoperating Obligations (NNO)
-5.58 -6.62 -0.04 -6.04 -29 -22 -17 -10 -27 -17 -10
Total Depreciation and Amortization (D&A)
0.34 0.33 0.34 0.56 0.49 0.56 0.58 0.56 0.63 0.67 0.64
Debt-free, Cash-free Net Working Capital to Revenue
-533.29% -634.02% -993.79% -208.61% -104.50% -80.06% -105.32% -213.39% -526.37% -450.42% -333.11%
Debt-free Net Working Capital to Revenue
-129.67% 270.77% -519.46% 250.51% 702.91% 490.46% 335.87% 90.23% 957.98% 656.47% 263.79%
Net Working Capital to Revenue
-129.67% 270.77% -606.06% 238.38% 691.65% 474.28% 311.88% 79.68% 949.82% 614.19% 221.79%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($1.13) ($0.36) ($0.98) ($2.56) ($0.26) ($0.30) ($0.34) ($0.75) ($0.12) ($0.31) ($0.10)
Adjusted Weighted Average Basic Shares Outstanding
8.26M 12.87M 13.71M 13.07M 25.69M 32.02M 32.03M 30.48M 34.52M 36.75M 36.86M
Adjusted Diluted Earnings per Share
($1.13) ($0.36) ($0.98) ($2.56) ($0.26) ($0.30) ($0.34) ($0.75) ($0.12) ($0.31) ($0.10)
Adjusted Weighted Average Diluted Shares Outstanding
8.26M 12.87M 13.71M 13.07M 25.69M 32.02M 32.03M 30.48M 34.52M 36.75M 36.86M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 ($2.56) $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
13.36M 13.37M 16.84M 28.60M 28.60M 28.62M 28.66M 32.17M 32.29M 32.72M 32.76M
Normalized Net Operating Profit after Tax (NOPAT)
-4.05 -3.96 -4.46 -33 -4.14 -4.93 -5.37 -17 -7.23 -6.38 -5.44
Normalized NOPAT Margin
-2,301.25% -3,811.63% -3,880.43% -2,229.21% -193.83% -951.08% -2,065.00% -1,508.78% -22,599.06% -2,670.54% -972.36%
Pre Tax Income Margin
-5,186.93% -4,355.77% -11,733.04% -2,255.11% -312.02% -1,880.70% -4,174.62% -2,015.36% -13,406.25% -4,711.30% -640.25%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
-607.60 -565.25 -434.26 -1,116.03 -229.03 -388.68 -373.28 -881.88 -185.52 -562.00 -209.53
NOPAT to Interest Expense
-432.46 -405.30 -305.18 -784.63 -164.11 -275.58 -266.68 -630.94 -134.31 -399.07 -151.36
EBIT Less CapEx to Interest Expense
-609.20 -589.13 -437.06 -1,123.17 -239.62 -402.64 -409.48 -938.77 -212.17 -600.95 -259.00
NOPAT Less CapEx to Interest Expense
-434.06 -429.18 -307.98 -791.76 -174.70 -289.54 -302.88 -687.83 -160.96 -438.02 -200.84
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% -1.49% -1.25% -2.27% -3.20% -2.09% -2.18% -0.97% -2.47% -2.77% -3.28%

Financials Breakdown Chart

Key Financial Trends

Oncocyte’s Q2 2026 financial statements show a sharp sequential revenue rebound, but the company remains deeply unprofitable and cash-flow negative. Revenue increased to $239,000 from $32,000 in Q1 2026, although it remained below the $518,000 reported in Q2 2025. The company’s small and volatile revenue base continues to be overshadowed by operating expenses.

  • Revenue improved sequentially. Q2 2026 revenue rose approximately 647% from Q1 2026, although the comparison benefits from an unusually weak $32,000 prior-quarter base.
  • Gross margin remained comparatively strong. Gross profit was $157,000 on $239,000 of revenue, representing a gross margin of approximately 66%, similar to Q2 2025.
  • Core operating costs declined sequentially. Selling, general and administrative expense fell to $2.9 million from $3.0 million, marketing expense declined to $1.9 million from $2.4 million, and research and development expense decreased to $4.5 million from $5.0 million.
  • Debt balances remain relatively modest. Short-term debt was $706,000 at June 30, 2026, down from $1.1 million in Q3 2025, while capital lease obligations declined to $915,000 from $1.3 million in Q1 2026.
  • Liquidity is concentrated in cash. Oncocyte reported $17.8 million of cash and equivalents plus $729,000 of restricted cash. Current assets of $20.5 million exceeded current liabilities of $10.3 million, but this liquidity position is being reduced quickly by ongoing operating losses.
  • Q2 financing did not provide a meaningful cash benefit. Net financing cash flow was negative $564,000, following a $26.0 million common-stock issuance in Q1. The company’s recent ability to raise equity has supported liquidity, but future financings could increase dilution.
  • Net losses worsened sequentially. The Q2 2026 net loss was $11.3 million, or $0.31 per share, compared with a $4.3 million loss, or $0.12 per share, in Q1 2026. The loss was also larger than the $9.7 million loss reported in Q2 2025.
  • Operating expenses remain far above revenue. Total operating expenses were $11.6 million in Q2, nearly 49 times quarterly revenue. A $2.3 million special charge also reversed the benefit from the $5.9 million special income recorded in Q1.
  • Cash burn accelerated. Operating activities consumed $9.3 million in Q2 2026, compared with $7.6 million in Q1 and $6.3 million in Q2 2025. Cash and equivalents fell by $10.6 million during the quarter, from $28.2 million to $17.8 million.
  • Shareholders’ equity remained negative. Total equity was negative $21.3 million at June 30, 2026, compared with negative $10.7 million at March 31. Total liabilities of $50.7 million exceeded total assets of $29.4 million, highlighting significant balance-sheet risk and the possibility of additional restructuring or equity financing.

Overall, the statements point to a company that has reduced some recurring expenses and retains a comparatively high gross margin, but has not yet demonstrated a sustainable revenue model. With revenue still below $1 million per quarter, operating losses exceeding $11 million and cash usage near $9 million per quarter, Oncocyte may need additional capital unless it can materially increase revenue or reduce spending.

11/17/26 03:23 PM ETAI Generated. May Contain Errors.

Oncocyte Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Oncocyte's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Oncocyte's net income appears to be on a downward trend, with a most recent value of -$50.22 million in 2025, falling from -$8.74 million in 2015. The previous period was -$60.66 million in 2024. Find out what analysts predict for Oncocyte in the coming months.

Oncocyte's total operating income in 2025 was -$51.12 million, based on the following breakdown:
  • Total Gross Profit: $2.30 million
  • Total Operating Expenses: $53.42 million

Over the last 10 years, Oncocyte's total revenue changed from $0.00 in 2015 to $4.06 million in 2025, a change of 405,500,000.0%.

In the past 12 quarters, Oncocyte's cash and equivalents has ranged from $3.36 million in Q3 2024 to $31.03 million in Q1 2025, and is currently $11.02 million as of their latest financial filing in Q3 2026.

Oncocyte had total debt of $2.12 million at the end of 2025, a 18.4% decrease from 2024, and none in 2015.

Over the last 10 years, Oncocyte's book value per share changed from 0.50 in 2015 to -1.10 in 2025.



Financial statements for NASDAQ:IMDX last updated on 11/17/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners